Is liraglutide treatment associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events : results from the Liraglutide Effect and Action in Diabetes ( LEAD ) trials?
Liraglutide was less immunogenic than exenatide; the frequency and levels of anti-liraglutide antibodies were low and did not impact glycemic efficacy or safety.
CKD was found to be independently associated with recurrent stroke, cardiovascular events or all-cause mortality in patients with RSSI.